Erythroplasia of Queyrat treated with imiquimod 5% cream: The necessity of regimen guidelines

Abstract

Key Clinical Message Development of noninvasive treatments for erythroplasia of Queyrat, a carcinoma in situ, is expected. This case suggests topical imiquimod might be a candidate with regimens consisting of much longer duration of the treatment than for genital warts and the maintenance phase of the treatment course to prevent the relapse.

Keywords

• carcinoma in situ
• erythroplasia of Queyrat
• imiquimod
• regimen guideline